Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan P Piccini

Showing results (431-440 of 538) with videos related to

Pageof 54
Sort By:
Pacing and Clinical Electrophysiology : PACE|June 24, 2020
Catheter ablation of atrial fibrillation in cardiac amyloidosisEric Black-Maier, Michael Rehorn, Rahul Loungani, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
BMJ Open|March 2, 2022
Heart Watch Study: protocol for a pragmatic randomised controlled trialSanket S Dhruva, Nilay D Shah, Sreekanth Vemulapalli, et al.
American Heart Journal|March 18, 2020
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillationFrederik Dalgaard, Rebecca North, Karen Pieper, et al.
JAMA Cardiology|November 29, 2018
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation IIUtibe R Essien, DaJuanicia N Holmes, Larry R Jackson, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Heart Rhythm O2|October 20, 2021
Optimizing mechanically sensed atrial tracking in patients with atrioventricular-synchronous leadless pacemakers: A single-center experienceKelly Arps, Jonathan P Piccini, Rebecca Yapejian, et al.
Journal of Cardiovascular Electrophysiology|January 14, 2022
Leadless pacemaker implantation after lead extraction for cardiac implanted electronic device infectionLi Bicong, John Carson Allen, Kelly Arps, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
Pageof 54

Showing results (431-440 of 538) with videos related to

Sort By:
Pageof 54
Pacing and Clinical Electrophysiology : PACE|June 24, 2020
Catheter ablation of atrial fibrillation in cardiac amyloidosisEric Black-Maier, Michael Rehorn, Rahul Loungani, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
BMJ Open|March 2, 2022
Heart Watch Study: protocol for a pragmatic randomised controlled trialSanket S Dhruva, Nilay D Shah, Sreekanth Vemulapalli, et al.
American Heart Journal|March 18, 2020
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillationFrederik Dalgaard, Rebecca North, Karen Pieper, et al.
JAMA Cardiology|November 29, 2018
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation IIUtibe R Essien, DaJuanicia N Holmes, Larry R Jackson, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Heart Rhythm O2|October 20, 2021
Optimizing mechanically sensed atrial tracking in patients with atrioventricular-synchronous leadless pacemakers: A single-center experienceKelly Arps, Jonathan P Piccini, Rebecca Yapejian, et al.
Journal of Cardiovascular Electrophysiology|January 14, 2022
Leadless pacemaker implantation after lead extraction for cardiac implanted electronic device infectionLi Bicong, John Carson Allen, Kelly Arps, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
Pageof 54